Navigation Links
Embryology study offers clues to birth defects
Date:6/9/2009

LA JOLLA, Calif., June 9, 2009 -- Gregg Duester, Ph.D., professor of developmental biology at Burnham Institute for Medical Research (Burnham), along with Xianling Zhao, Ph.D., and colleagues, have clarified the role that retinoic acid plays in limb development. The study showed that retinoic acid controls the development (or budding) of forelimbs, but not hindlimbs, and that retinoic acid is not responsible for patterning (or differentiation of the parts) of limbs. This research corrects longstanding misconceptions about limb development and provides new insights into congenital limb defects. The study was published online in the journal Current Biology on May 21.

In studies of mice and zebrafish, the team found that retinoic acid suppresses the gene fibroblast growth factor 8 (Fgf8) during the period when forelimb budding occurs, creating a suitable environment for the creation of forelimb buds.

"For decades, it was thought that retinoic acid controlled limb patterning, such as defining the thumb as being different from the little finger," said Dr. Duester. "However, we have demonstrated in mice that retinoic acid is not required for limb patterning, but rather is necessary to initiate the limb budding process. We also found that retinoic acid was unnecessary for hindlimb (leg) budding, but was needed for forelimb (arm) budding."

Congenital birth defects of the arms, legs, hands or feet result from improper development of limb bud tissues during embryogenesis. These processes are regulated by signaling molecules that control the growth and differentiation of progenitor cells by regulating specific genes. One of these signaling molecules is retinoic acid, a metabolite produced from vitamin A (retinol), which plays a key role in the development of limbs and other organs. Dr. Duester's lab was instrumental in identifying Raldh2 and Raldh3, the genes responsible for retinoic acid synthesis, and has shown that retinoic acid is only produced by certain cells at precise stages of development.

In the study, the team of scientists showed that mice missing the Raldh2 and Raldh3 genes, which normally die early and do not develop limbs, could be rescued by treatment with a small dose of retinoic acid. However, forelimb development was stunted, suggesting that retinoic acid is required for forelimb but not hindlimb development. In zebrafish, the forelimb (pectoral fin) is also missing in retinoic acid-deficient embryos, but they were able to rescue fin development by treating such embryos with a drug that reduces fibroblast growth factor activity, thus supporting the hypothesis that retinoic acid normally reduces this activity.

By providing a more complete understanding of the molecular mechanisms involved in normal limb development, these findings may lead to new therapeutic or preventative measures to combat congenital limb defects, such as Holt-Oram syndrome, a birth defect characterized by upper limb and heart defects.


'/>"/>

Contact: Josh Baxt
jbaxt@burnham.org
858-795-5236
Burnham Institute
Source:Eurekalert

Related biology news :

1. Colon cancer screening technique shows continued promise in new study
2. Study finds colorectal cancer rates increasing worldwide
3. MU study finds connection between evolution, classroom learning
4. Study: Illegal fishing harming present and future New England groundfish fisheries
5. Jefferson receives $1.7 million grant to study stem cells in intervertebral discs of the spine
6. Simple drug treatment may prevent nicotine-induced SIDS: Study
7. Tulane receives grant to study limb regeneration
8. CU-Boulder study shows 53 million-year-old high Arctic mammals wintered in darkness
9. New study finds lowfat chocolate milk is effective post-exercise recovery aid for soccer players
10. International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
11. IFAR contributes to study that finds genes that influence the start of menstruation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... -- Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently symptomatic therapies for ... recent study published in STEM CELLS suggests that human neural stem cell (hNSC) ... to produce more neural cells. , Strategies involving transplantation of these cells ...
(Date:3/28/2017)... Triangle Park, NC (PRWEB) , ... March 28, ... ... development company engaged in the development of a new orally administered treatment for ... Advisory Board. , CEO John Didsbury states, “As we seek to uniquely treat ...
Breaking Biology Technology: